Literature DB >> 20805756

Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.

Paul A Nakonezny1, Thomas J Carmody, David W Morris, Benji T Kurian, Madhukar H Trivedi.   

Abstract

The inability to experience pleasure, anhedonia, is recognized as a hallmark symptom of depression. An instrument developed for the assessment of hedonic capacity is the 14-item, self-report, Snaith-Hamilton Pleasure Scale (SHAPS), but its psychometric properties have not been adequately evaluated. This study examined the reliability and validity of the SHAPS using a large sample of adult outpatients with major depressive disorder (MDD). Data for this study were obtained from 461 adult outpatients with a diagnosis of MDD who participated in Implementation of Algorithms using Computerized Treatment Systems Project. Internal consistency of the SHAPS was assessed using the Cronbach's coefficient α. A principal factor analysis was used to define the dimensionality of the SHAPS. Convergent and discriminant validity was assessed by evaluating the Pearson correlations between the SHAPS total score and the pleasure/enjoyment item of the 30-item Inventory of Depressive Symptomatology - Clinician-rating (IDS-C30); Quality of Life, Enjoyment, and Satisfaction Questionnaire; 17-item Hamilton Rating Scale for Depression; IDS-C30; 16-item Quick Inventory of Depressive Symptomatology; and 10-item clinician-rated Montgomery-Asberg Depression Rating Scale, respectively. The internal consistency of the SHAPS was 0.91. A one-factor solution emerged for the SHAPS (eigen-values of the first two initial factors were 5.95 and 0.43, respectively). Pearson correlations revealed a positive linear relationship between the SHAPS total score and the total scores on the 17-item Hamilton Rating Scale for Depression (r=0.49, P<0.0001), IDS-C30 (r=0.56, P<0.0001), 16-item Quick Inventory of Depressive Symptomatology (r=0.55, P<0.0001), and 10-item clinician-rated Montgomery-Asberg Depression Rating Scale (r=0.53, P<0.0001). The SHAPS total score was negatively correlated with the Quality of Life, Enjoyment, and Satisfaction Questionnaire (r=-0.65, P<0.0001). This study shows that the SHAPS is a reliable, valid, and unidimensional instrument used to assess the hedonic capacity in adult outpatients with MDD.

Entities:  

Mesh:

Year:  2010        PMID: 20805756      PMCID: PMC2957191          DOI: 10.1097/YIC.0b013e32833eb5ee

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  18 in total

1.  Structural validity of MADRS during antidepressant treatment.

Authors:  A Galinowski; P Lehert
Journal:  Int Clin Psychopharmacol       Date:  1995-09       Impact factor: 1.659

2.  Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.

Authors:  A Khan; S R Khan; E B Shankles; N L Polissar
Journal:  Int Clin Psychopharmacol       Date:  2002-11       Impact factor: 1.659

3.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

4.  A comparison of two rating scales for depression.

Authors:  J J Schwab; M R Bialow; C E Holzer
Journal:  J Clin Psychol       Date:  1967-01

5.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

6.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.

Authors:  M H Trivedi; A J Rush; H M Ibrahim; T J Carmody; M M Biggs; T Suppes; M L Crismon; K Shores-Wilson; M G Toprac; E B Dennehy; B Witte; T M Kashner
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

7.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

8.  Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients.

Authors:  Marianna Mazza; Maria Rosaria Squillacioti; Riccardo Daniele Pecora; Luigi Janiri; Pietro Bria
Journal:  Psychiatry Res       Date:  2008-10-30       Impact factor: 3.222

Review 9.  Anhedonia: a neglected symptom of psychopathology.

Authors:  P Snaith
Journal:  Psychol Med       Date:  1993-11       Impact factor: 7.723

10.  The Inventory of Depressive Symptomatology (IDS): psychometric properties.

Authors:  A J Rush; C M Gullion; M R Basco; R B Jarrett; M H Trivedi
Journal:  Psychol Med       Date:  1996-05       Impact factor: 7.723

View more
  38 in total

1.  Anhedonia in Trauma-Exposed Individuals: Functional Connectivity and Decision-Making Correlates.

Authors:  Elizabeth A Olson; Roselinde H Kaiser; Diego A Pizzagalli; Scott L Rauch; Isabelle M Rosso
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-11-16

2.  Altered neural reward and loss processing and prediction error signalling in depression.

Authors:  Bettina Ubl; Christine Kuehner; Peter Kirsch; Michaela Ruttorf; Carsten Diener; Herta Flor
Journal:  Soc Cogn Affect Neurosci       Date:  2015-01-06       Impact factor: 3.436

3.  Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression.

Authors:  Arpana Agrawal; Elliot C Nelson; Andrew K Littlefield; Kathleen K Bucholz; Louisa Degenhardt; Anjali K Henders; Pamela A F Madden; Nicholas G Martin; Grant W Montgomery; Michele L Pergadia; Kenneth J Sher; Andrew C Heath; Michael T Lynskey
Journal:  Arch Gen Psychiatry       Date:  2012-07

4.  Measuring Anhedonia in Adolescents: A Psychometric Analysis.

Authors:  Adam M Leventhal; Jennifer B Unger; Janet Audrain-McGovern; Steve Sussman; Heather E Volk; David R Strong
Journal:  J Pers Assess       Date:  2015-04-20

5.  Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR): Results From the STRIDE (CTN-0037) Study.

Authors:  Joseph M Trombello; Michael O Killian; Allen Liao; Katherine Sanchez; Tracy L Greer; Robrina Walker; Bruce Grannemann; Chad D Rethorst; Thomas Carmody; Madhukar H Trivedi
Journal:  J Clin Psychiatry       Date:  2018 Mar/Apr       Impact factor: 4.384

6.  Evaluation of anhedonia with the Snaith-Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder.

Authors:  Paul A Nakonezny; David W Morris; Tracy L Greer; Matthew J Byerly; Thomas J Carmody; Bruce D Grannemann; Ira H Bernstein; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2015-03-21       Impact factor: 4.791

7.  Anhedonia in melancholic and non-melancholic depressive disorders.

Authors:  Kathryn Fletcher; Gordon Parker; Amelia Paterson; Maurizio Fava; Dan Iosifescu; Diego A Pizzagalli
Journal:  J Affect Disord       Date:  2015-05-21       Impact factor: 4.839

8.  Individuals with more severe depression fail to sustain nucleus accumbens activity to preferred music over time.

Authors:  Lisanne M Jenkins; Kristy A Skerrett; Sophie R DelDonno; Víctor G Patrón; Kortni K Meyers; Scott Peltier; Jon-Kar Zubieta; Scott A Langenecker; Monica N Starkman
Journal:  Psychiatry Res Neuroimaging       Date:  2018-03-05       Impact factor: 2.376

Review 9.  Assessing anhedonia in depression: Potentials and pitfalls.

Authors:  Sakina J Rizvi; Diego A Pizzagalli; Beth A Sproule; Sidney H Kennedy
Journal:  Neurosci Biobehav Rev       Date:  2016-03-06       Impact factor: 8.989

10.  Anhedonia is associated with blunted reward sensitivity in first-degree relatives of patients with major depression.

Authors:  Wen-Hua Liu; Jonathan P Roiser; Ling-Zhi Wang; Yu-Hua Zhu; Jia Huang; David L Neumann; David H K Shum; Eric F C Cheung; Raymond C K Chan
Journal:  J Affect Disord       Date:  2015-11-10       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.